XML 48 R31.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details) - Customer Concentration Risk | 12 Months Ended
--- | ---
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019
Sales revenue, net | Incyte Corporation (Incyte) |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 31.00% | 47.00% | 35.00%
Sales revenue, net | Janssen Biotech Inc. |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable |  | 19.00% | 0.00%
Sales revenue, net | Zai Lab Limited (Zai Lab) |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 30.00% | 11.00% | 29.00%
Sales revenue, net | Les Laboratoires Servier And Institut De Recherches Servier (Servier) [Member] |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 0.00% |  | 18.00%
Sales revenue, net | Imab |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 16.00% |  |
Accounts receivable | Janssen Biotech Inc. |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable |  | 87.00% |
Accounts receivable | Zai Lab |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 23.00% |  |
Accounts receivable | Imab |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 12.00% | 0.00% |
Accounts receivable | McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC [Member] |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 18.00% | 0.00% |
Accounts receivable | ASD Healthcare and Oncology Supply [Member] |  |  |
Concentration Risk [Line Items] |  |  |
Percentage of significant accounts receivable | 18.00% | 0.00% |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ConcentrationRiskLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_IncyteCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_JanssenBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_LesLaboratoiresServierAndInstitutDeRecherchesServierServierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_ImabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_ZaiLabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mgnx_ASDHealthcareAndOncologySupplyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |